https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52384 Wed 28 Feb 2024 15:35:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45109 n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.]]> Wed 26 Oct 2022 13:22:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27478 Wed 23 Feb 2022 16:03:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53423 Wed 17 Apr 2024 14:39:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55657 80% of participants as essential. Of those, for 22 items, <80% reported the care as received. Gaps were identified in relation to GP consultation (1 item), preparation (1 item) subsequent decision making for treatment (1 item), prognosis (6 items) and post-treatment follow-up (1 item). Conclusions: Areas were identified where actual care fell short of patients' perceptions of essential care.]]> Wed 12 Jun 2024 10:07:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54626 Wed 06 Mar 2024 10:52:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38904 P < 0.001), with higher rates of atrial fibrillation, hypertension and diabetes mellitus. Stroke complicating cardiac catheterisation was associated with an increased risk of readmission, with a significantly higher hazard of readmission for stroke noted. Despite minimal functional impairment based on modified Rankin score, stroke was associated with a significant risk of early and cumulative mortality. Stroke incidence remained stable over the study period despite changes in procedural practice. Conclusions: The incidence and functional severity of stroke remains low despite evolving procedural practice with a stable incidence over time despite changes in procedural practice; however, post-procedural stroke confirms an increased mortality hazard.]]> Wed 02 Mar 2022 12:28:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45700 2) to provide reperfusion to patients with STEMI involve a 12-lead electrocardiogram in the ambulance, discussion between cardiologist and paramedic, followed by pre-hospital thrombolysis (PHT) delivered in ambulance to appropriate patients >60 min from the cardiac catheterisation laboratories. Patients who can access the cardiac catheterisation laboratories within 60 min are treated with primary percutaneous coronary intervention (PCI). Aims: We have previously reported excellent 12-month outcomes for patients receiving PHT and the aim of the current analysis is to look at the long term outcomes. Methods: We assessed long-term all-cause mortality and major adverse cardiovascular events of STEMI patients undergoing PHT in our health district from August 2008 to August 2013 and compared with the primary PCI group. Results: One hundred and fifty (mean age: 62 ± 13 years, males: 76%, n = 114) patients were administered PHT and 334 patients (mean age: 65 ± 13 years, males: 75%, n = 251) underwent primary PCI during the study period. During a median follow up of 6.2 years (interquartile range: 4.8–7.4 years) all-cause mortality was 16% and 19% in the PHT and primary PCI groups respectively (P = 0.4). Conclusion: Our real-world experience shows that PHT followed by early transfer to a primary PCI-capable centre is an effective reperfusion strategy, with comparable results to primary PCI, and mortality benefits are sustained to more than 6 years.]]> Thu 29 Jun 2023 13:40:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37046 Thu 13 Aug 2020 12:00:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10611 Sat 24 Mar 2018 08:13:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49543 Mon 22 May 2023 08:45:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49532 Mon 22 May 2023 08:38:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50968 Mon 14 Aug 2023 15:20:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36539 p = 0.008). MAMI patients compared to treated STEMI patients had higher 30 day readmission (31.6% vs 3.3%, p = 0.001) and longer length of stay (5.5 vs 4.3 days p = 0.029). Inaccurate identification of STEMI on electrocardiogram (72%) and diagnostic uncertainty (65%) were associated with MAMI. The Glasgow algorithm to identify STEMI was utilised on 57% of occasions, with 93% accuracy. Conclusion: Mortality following MAMI is high particularly in smaller rural hospitals. MAMI results in increased length of stay and readmission rate. Electrocardiogram interpretation and diagnostic accuracy require improvement to determine if this improves patient outcomes.]]> Fri 29 May 2020 17:22:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41821 2.2 mm. Conclusions: Nurses can lead the assessment of RA occlusion using ultrasound to enhance planning and care, including monitoring compression times to reduce RAO.]]> Fri 12 Aug 2022 12:52:20 AEST ]]>